LATDE DIAGNOSTICS CORP.

Medtech · Private

Rapid antibiotic susceptibility test (MAAP assay) for urinary tract infections using metabolic labeling and immunodetection

Grants
$571K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Rapid, equitable, lateral flow-based antibiotic susceptibility testing for urinary tract infections$299,170
Federal grantDepartment of Health and Human Services · Phase I · Rapid lateral flow-based antibiotic susceptibility testing for urinary tract infections$272,184
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1162Levita Magnetics International Corp.—$51M
1163Spiral Therapeutics Inc—$37M
1164SONALASENSE, INC.—$35M
1165LATDE DIAGNOSTICS CORP.——
1166AUTHENTAG LLC——
1167Logiq.ai Inc.—$1.5M
1168APTUS BIOSCIENCES LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.